Discovery of a novel site of opioid action at the innate immune pattern-recognition receptor TLR4 and its role in addiction

International Review of Neurobiology

Volumn 118, Issue , 2014, Pages 129-163

  Jacobsen, Jonathan Henry W ^a   Watkins, Linda R ^b   Hutchinson, Mark R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Addiction; Allostasis; Chemokine; Cytokine; Glia; Innate immune; Neurokine; Opioids; Toll like receptor

Indexed keywords

CHEMOKINE; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; LIPOPOLYSACCHARIDE; OPIATE; TOLL LIKE RECEPTOR 4; 4 AMINOBUTYRIC ACID; CYCLOOXYGENASE 2; DYNORPHIN; EXCITATORY AMINO ACID TRANSPORTER; GLIAL FIBRILLARY ACIDIC PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; N METHYL DEXTRO ASPARTIC ACID; PATTERN RECOGNITION RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; NARCOTIC ANALGESIC AGENT;

AFFECT; ALLOSTASIS; ARTICLE; BEHAVIOR CHANGE; BRAIN REGION; CENTRAL NERVOUS SYSTEM FUNCTION; GLIA CELL; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; IMMUNE RESPONSE; IMMUNOSTIMULATION; INNATE IMMUNITY; INTOXICATION; MOLECULAR RECOGNITION; NEUROIMMUNOLOGY; NEUROSCIENCE; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; REWARD; STRESS; WITHDRAWAL SYNDROME; ADAPTATION; ASTROCYTE; CELL ACTIVATION; CELL HETEROGENEITY; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; DOPAMINERGIC TRANSMISSION; DOWN REGULATION; DRUG ACTIVITY; EUPHORIA; HOST RESISTANCE; MICROGLIA; MOLECULAR DOCKING; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROTRANSMISSION; NUCLEUS ACCUMBENS; PERIAQUEDUCTAL GRAY MATTER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REINFORCEMENT; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; SYNAPSE; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANALGESICS, OPIOID; ANIMALS; CYTOKINES; HUMANS; IMMUNITY, INNATE; MICROGLIA; OPIOID-RELATED DISORDERS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84906732261     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-801284-0.00006-3     Document Type: Chapter

References (121)

1. Adler M.W., Rogers T.J. Are chemokines the third major system in the brain?. Journal of Leukocyte Biology 2005, 78(6):1204-1209.
2. Akira S., Takeda K. Toll-like receptor signalling. Nature Reviews Immunology 2004, 4(7):499-511.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatry Press, Washington, D.C. 4th ed.
4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2013, American Psychiatric Association, Washington, D.C. 5th ed.
5. Banati R.B. Neuropathological imaging: In vivo detection of glial activation as a measure of disease and adaptive change in the brain. British Medical Bulletin 2003, 65:121-131.
6. Ben Achour S., Pascual O. Glia: The many ways to modulate synaptic plasticity. Neurochemistry International 2010, 57(4):440-445.
7. Besedovsky H.O., Rey A.D. Physiology of psychoneuroimmunology: A personal view. Brain, Behavior, and Immunity 2007, 21(1):34-44.
8. Bilbo S.D., Schwarz J.M. The immune system and developmental programming of brain and behavior. Frontiers in Neuroendocrinology 2012, 33(3):267-286.
9. Bland S.T., Hutchinson M.R., Maier S.F., Watkins L.R., Johnson K.W. The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release. Brain, Behavior, and Immunity 2009, 23(4):492-497.
10. Bossert J.M., Ghitza U.E., Lu L., Epstein D.H., Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: An update and clinical implications. European Journal of Pharmacology 2005, 526(1-3):36-50.
11. Bossert J.M., Marchant N.J., Calu D.J., Shaham Y. The reinstatement model of drug relapse: Recent neurobiological findings, emerging research topics, and translational research. Psychopharmacology 2013, 229(3):453-476.
12. Bozarth M.A., Wise R.A. Intracranial self-administration of morphine into the ventral tegmental area in rats. Life Sciences 1981, 28(5):551-555.
13. Bsibsi M., Ravid R., Gveric D., van Noort J.M. Broad expression of Toll-like receptors in the human central nervous system. Journal of Neuropathology and Experimental Neurology 2002, 61(11):1013-1021.
14. Bushong E.A., Martone M.E., Jones Y.Z., Ellisman M.H. Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. Journal of Neuroscience 2002, 22(1):183-192.
15. Capuron L., Miller A.H. Immune system to brain signaling: Neuropsychopharmacological implications. Pharmacology and Therapeutics 2011, 130(2):226-238.
16. Coller J.K., Hutchinson M.R. Implications of central immune signaling caused by drugs of abuse: Mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence. Pharmacology and Therapeutics 2012, 134(2):219-245.
17. Cushman P., Dole V.P. Detoxification of rehabilitated methadone-maintained patients. JAMA 1973, 226(7):747-752.
18. Dang V.C., Christie M.J. Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons. British Journal of Pharmacology 2012, 165(6):1704-1716.
19. Dantzer R. Cytokine-induced sickness behavior: Mechanisms and implications. Annals of the New York Academy of Sciences 2001, 933:222-234.
20. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: When the immune system subjugates the brain. Nature Reviews Neuroscience 2008, 9(1):46-56.
21. De Leo J.A., Tawfik V.L., LaCroix-Fralish M.L. The tetrapartite synapse: Path to CNS sensitization and chronic pain. Pain 2006, 122(1-2):17-21.
22. Degenhardt L., Whiteford H.A., Ferrari A.J., Baxter A.J., Charlson F.J., Hall W.D., et al. Global burden of disease attributable to illicit drug use and dependence: Findings from the Global Burden of Disease Study 2010. The Lancet 2013, 382(9904):1564-1574.
23. Di Chiara G. Drug addiction as dopamine-dependent associative learning disorder. European Journal of Pharmacology 1999, 375(1-3):13-30.
24. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Sciences 1988, 85(14):5274-5278.
25. Eidson L.N., Murphy A.Z. Blockade of toll-like receptor 4 attenuates morphine tolerance and facilitates the pain relieving properties of morphine. Journal of Neuroscience 2013, 33(40):15952-15963.
26. Felger J.C., Lotrich F.E. Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications. Neuroscience 2013, 246:199-229.
27. Fellin T. Communication between neurons and astrocytes: Relevance to the modulation of synaptic and network activity. Journal of Neurochemistry 2009, 108(3):533-544.
28. Feltenstein M.W., See R.E. The neurocircuitry of addiction: An overview. British Journal of Pharmacology 2009, 154(2):261-274.
29. Frank M.G., Watkins L.R., Maier S.F. Stress- and glucocorticoid-induced priming of neuroinflammatory responses: Potential mechanisms of stress-induced vulnerability to drugs of abuse. Brain, Behavior, and Immunity 2011, 25(S1):S21-S28.
30. Gárate I., García-Bueno B., Madrigal J.L., Bravo L., Berrocoso E., Caso J.R., et al. Origin and consequences of brain toll-like receptor 4 pathway stimulation in an experimental model of depression. Journal of Neuroinflammation 2011, 8(1):151.
31. Gárate I., Garcia-Bueno B., Madrigal J.L.M., Caso J.R., Alou L., Gomez-Lus M.L., et al. Stress-induced neuroinflammation: Role of the toll-like receptor-4 pathway. Biological Psychiatry 2013, 73(1):32-43.
32. Graeber M.B. Changing face of microglia. Science 2010, 330(6005):783-788.
33. Guyon A., Skrzydelski D., De Giry I., Rovère C., Conductier G., Trocello J.M., et al. Long term exposure to the chemokine Ccl2 activates the nigrostriatal dopamine system: A novel mechanism for the control of dopamine release. Neuroscience 2009, 162(4):1072-1080.
34. Gysling K., Wang R.Y. Morphine-induced activation of A10 dopamine neurons in the rat. Brain Research 1983, 277(1):119-127.
35. Halassa M.M., Fellin T., Takano H., Dong J.H., Haydon P.G. Synaptic islands defined by the territory of a single astrocyte. Journal of Neuroscience 2007, 27(24):6473-6477.
36. Hao S., Liu S., Zheng X., Zheng W., Ouyang H., Mata M., et al. The role of TNF. Neuropsychopharmacology 2010, 36(3):664-676.
37. Hart B.L. Biological basis of the behavior of sick animals. Neuroscience and Biobehavioral Reviews 1988, 12(2):123-137.
38. Heinrichs S.C., Menzaghi F., Schulteis G., Koob G.F., Stinus L. Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behavioural Pharmacology 1995, 6(1):74-80.
39. Henry C.J., Huang Y., Wynne A., Hanke M., Himler J., Bailey M.T., et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. Journal of Neuroinflammation 2008, 5(1):1-15.
40. Hnasko T.S., Sotak B.N., Palmiter R.D. Morphine reward in dopamine-deficient mice. Nature 2005, 438(7069):854-857.
41. Hutchinson M.R., Bland S.T., Johnson K.W., Rice K.C., Maier S.F., Watkins L.R. Opioid-induced glial activation: Mechanisms of activation and implications for opioid analgesia, dependence, and reward. The Scientific World Journal 2007, 7:98-111.
42. Hutchinson M.R., Lewis S.S., Coats B.D., Skyba D.A., Crysdale N.Y., Berkelhammer D.L., et al. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (Ibudilast). Brain, Behavior, and Immunity 2009, 23(2):240-250.
43. Hutchinson M.R., Northcutt A.L., Chao L.W., Kearney J.J., Zhang Y., Berkelhammer D.L., et al. Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain, Behavior, and Immunity 2008, 22(8):1248-1256.
44. Hutchinson M.R., Northcutt A.L., Hiranita T., Wang X., Lewis S.S., Thomas J., et al. Opioid activation of toll-like receptor 4 contributes to drug reinforcement. Journal of Neuroscience 2012, 32(33):11187-11200.
45. Hutchinson M.R., Shavit Y., Grace P.M., Rice K.C., Maier S.F., Watkins L.R. Exploring the neuroimmunopharmacology of opioids: An integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacological Reviews 2011, 63(3):772-810.
46. Hutchinson M.R., Watkins L.R. Why is neuroimmunopharmacology crucial for the future of addiction research?. Neuropharmacology 2014, 76:218-227.
47. Hutchinson M.R., Zhang Y., Brown K., Coats B.D., Shridhar M., Sholar P.W., et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). European Journal of Neuroscience 2008, 28(1):20-29.
48. Hutchinson M.R., Zhang Y., Shridhar M., Evans J.H., Buchanan M.M., Zhao T.X., et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain, Behavior, and Immunity 2010, 24(1):83-95.
49. Iwata M., Ota K.T., Duman R.S. The inflammasome: Pathways linking psychological stress, depression and systemic illness. Brain, Behavior, and Immunity 2013, 31(C):105-114.
50. Jensen C.J., Massie A., Keyser J. Immune players in the CNS: The astrocyte. Journal of Neuroimmune Pharmacology 2013, 8(4):824-839.
51. Johnson J.D., Campisi J., Sharkey C.M., Kennedy S.L., Nickerson M., Greenwood B.N., et al. Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. Neuroscience 2005, 135(4):1295-1307.
52. Johnson S.W., North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. The Journal of Neuroscience 1992, 12(2):483-488.
53. Kageyama K., Kagaya S., Takayasu S., Hanada K., Iwasaki Y., Suda T. Cytokines induce NF-K{green}B, Nurr1 and corticotropin-releasing factor gene transcription in hypothalamic 4B cells. Neuroimmunomodulation 2010, 17(5):305-313.
54. Kawai T., Akira S. Signaling to NF-κB by toll-like receptors. Trends in Molecular Medicine 2007, 13(11):460-469.
55. Kelley K.W., Bluthé R.-M., Dantzer R., Zhou J.-H., Shen W.-H., Johnson R.W., et al. Cytokine-induced sickness behavior. Brain, Behavior, and Immunity 2003, 17(Suppl. 1):S112-S118.
56. Koob G.F. Neural mechanisms of drug reinforcement. Annals of the New York Academy of Sciences 1992, 654:171-191.
57. Koob G.F. Drug abuse: Hedonic homeostatic dysregulation. Science 1997, 278(5335):52-58.
58. Koob G.F. Addiction is a reward deficit and stress surfeit disorder. Frontiers in Psychiatry 2013, 4:1-18.
59. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001, 24(2):97-129.
60. Koob G.F., Le Moal M. Addiction and the brain antireward system. Annual Review of Psychology 2008, 59(1):29-53.
61. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2009, 35(1):217-238.
62. Kosten T.R., George T.P. The neurobiology of opioid dependence: Implications for treatment. Science & Practice Perspectives 2002, 1(1):13-20.
63. Krebs M.O., Gauchy C., Desban M., Glowinski J., Kemel M.L. Role of dynorphin and GABA in the inhibitory regulation of NMDA-induced dopamine release in striosome- and matrix-enriched areas of the rat striatum. Journal of Neuroscience 1994, 14(4):2435-2443.
64. Latz E., Xiao T.S., Stutz A. Activation and regulation of the inflammasomes. Nature Review Immunology 2013, 13(6):397-411.
65. Liu L., Coller J.K., Watkins L.R., Somogyi A.A., Hutchinson M.R. Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: Comparison of different mouse strains. Brain, Behavior, and Immunity 2011, 25(6):1223-1232.
66. Lunden J.W., Kirby L.G. Opiate exposure and withdrawal dynamically regulate mRNA expression in the serotonergic dorsal raphe nucleus. Neuroscience 2013, 254(C):160-172.
67. Matsui A., Williams J.T. Opioid-sensitive GABA inputs from rostromedial tegmental nucleus synapse onto midbrain dopamine neurons. Journal of Neuroscience 2011, 31(48):17729-17735.
68. Matthews R.T., German D.C. Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine. Neuroscience 1984, 11(3):617-625.
69. McGee D.W., Bamberg T., Vitkus S.J., McGhee J.R. A synergistic relationship between TNF-alpha, IL-1 beta, and TGF-beta 1 on IL-6 secretion by the IEC-6 intestinal epithelial cell line. Immunology 1995, 86(1):6-11.
70. Miguel-Hidalgo J.J. The role of glial cells in drug abuse. Current Drug Abuse Reviews 2009, 2(1):76-82.
71. Morgan M.M., Christie M.J. Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. British Journal of Pharmacology 2012, 164(4):1322-1334.
72. Najjar S., Pearlman D.M., Alper K., Najjar A., Devinsky O. Neuroinflammation and psychiatric illness. Journal of Neuroinflammation 2013, 10(43):1-24.
73. Narita M., Miyatake M., Narita M., Shibasaki M., Shindo K., Nakamura A., et al. Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology 2006, 31(11):2476-2488.
74. National Institute of Drug Abuse Heroin: Abuse and addiction (National Institute of Drug Abuse Research Report Series) 2005, National Institute of Health, Bethesda.
75. National Institute of Drug Abuse Commonly abused prescription drugs (National Institute of Drug Abuse) 2011, National Institute of Drug Abuse, Bethesda.
76. Navarro-Zaragoza J., Nunez C., Laorden M.L., Milanes M.V. Effects of corticotropin-releasing factor receptor-1 antagonists on the brain stress system responses to morphine withdrawal. Molecular Pharmacology 2010, 77(5):864-873.
77. Navarro-Zaragoza J., Núñez C., Ruiz-Medina J., Laorden M.L., Valverde O., Milanés M.V. CRF2 mediates the increased noradrenergic activity in the hypothalamic paraventricular nucleus and the negative state of morphine withdrawal in rats. British Journal of Pharmacology 2011, 162(4):851-862.
78. Nimmerjahn A. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308(5726):1314-1318.
79. Nish S., Medzhitov R. Host defense pathways: Role of redundancy and compensation in infectious disease phenotypes. Immunity 2011, 34(5):629-636.
80. O'Connor K.A., Johnson J.D., Hansen M.K., Wieseler Frank J.L., Maksimova E., Watkins L.R., et al. Peripheral and central proinflammatory cytokine response to a severe acute stressor. Brain Research 2003, 991(1-2):123-132.
81. Ouyang H., Liu S., Zeng W., Levitt R.C., Candiotti K.A., Hao S. An emerging new paradigm in opioid withdrawal: A critical role for glia-neuron signaling in the periaqueductal gray. The Scientific World Journal 2012, 2012(24):1-9.
82. Palin K., Bluthé R.-M., McCusker R.H., Moos F., Dantzer R., Kelley K.W. TNFα-induced sickness behavior in mice with functional 55 kD TNF receptors is blocked by central IGF-I. Journal of Neuroimmunology 2007, 187(1-2):55-60.
83. Phillips A.G., LePiane F.G. Reinforcing effects of morphine microinjection into the ventral tegmental area. Pharmacology, Biochemistry and Behavior 1980, 12(6):965-968.
84. Poltorak A. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 1998, 282(5396):2085-2088.
85. Pribiag H., Stellwagen D. TNF-downregulates inhibitory neurotransmission through protein phosphatase 1-dependent trafficking of GABAA receptors. Journal of Neuroscience 2013, 33(40):15879-15893.
86. Quan N., Banks W.A. Brain-immune communication pathways. Brain, Behavior, and Immunity 2007, 21(6):727-735.
87. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends in Immunology 2006, 27(1):24-31.
88. Ransohoff R.M., Brown M.A. Innate immunity in the central nervous system. Journal of Clinical Investigation 2012, 122(4):1164-1171.
89. Ransohoff R.M., Perry V.H. Microglial physiology: Unique stimuli, specialized responses. Annual Review of Immunology 2009, 27(1):119-145.
90. Risbrough V.B. Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. Journal of Neuroscience 2004, 24(29):6545-6552.
91. Robinson T.E., Berridge K.C. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Research Reviews 1993, 18(3):247-291.
92. Rogers J.L., Ghee S., See R.E. The neural circuitry underlying reinstatement of heroin-seeking behavior in an animal model of relapse. Neuroscience 2008, 151(2):579-588.
93. Savin C., Triesch J., Meyer-Hermann M. Epileptogenesis due to glia-mediated synaptic scaling. Journal of the Royal Society Interface 2009, 6(37):655-668.
94. Schwarz J.M., Bilbo S.D. Adolescent morphine exposure affects long-term microglial function and later-life relapse liability in a model of addiction. Journal of Neuroscience 2013, 33(3):961-971.
95. Schwarz J.M., Hutchinson M.R., Bilbo S.D. Early-life experience decreases drug-induced reinstatement of morphine CPP in adulthood via microglial-specific epigenetic programming of anti-inflammatory IL-10 expression. Journal of Neuroscience 2011, 31(49):17835-17847.
96. Shekhar A., Truitt W., Rainnie D., Sajdyk T. Role of stress, corticotrophin releasing factor (CRF) and amygdala plasticity in chronic anxiety. Stress 2005, 8(4):209-219.
97. Shurman J., Koob G.F., Gutstein H.B. Opioids, pain, the brain, and hyperkatifeia: A framework for the rational use of opioids for pain. Pain Medicine 2010, 11(7):1092-1098.
98. Si J., Yang J., Xue L., Yang C., Luo Y., Shi H., et al. Activation of NF-κB in basolateral amygdala is required for memory reconsolidation in auditory fear conditioning. PloS One 2012, 7(9):e43973.
99. Smith M.F., Mitchell A., Li G., Ding S., Fitzmaurice A.-M., Ryan K., et al. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-κB activation and chemokine expression by epithelial cells. Journal of Biological Chemistry 2003, 278(35):32552-32560.
100. Sofroniew M.V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends in Neurosciences 2009, 32(12):638-647.
101. Sofroniew M.V., Vinters H.V. Astrocytes: Biology and pathology. Acta Neuropathologica 2009, 119(1):7-35.
102. Solomon R.L., Corbit J.D. An opponent-process theory of motivation. I. Temporal dynamics of affect. Psychological Review 1974, 81(2):119-145.
103. Song C., Merali Z., Anisman H. Variations of nucleus accumbens dopamine and serotonin following systemic Interleukin-1, Interleukin-2 or Interleukin-6 treatment. Neuroscience 1999, 88(3):823-836.
104. Song P., Zhoa Z.-Q. The involvement of glial cells in the development of morphine tolerance. Neuroscience Research 2001, 39:281-286.
105. Stellwagen D. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor. Journal of Neuroscience 2005, 25(12):3219-3228.
106. Stevens C.W., Aravind S., Das S., Davis R.L. Pharmacological characterization of LPS and opioid interactions at the toll-like receptor 4. British Journal of Pharmacology 2013, 168(6):1421-1429.
107. Szabo A., Rajnavolgyi E. Collaboration of toll-like and RIG-1-like receptors in human dendritic cells: Triggering antiviral innate immune responses. American Journal of Clinical and Experimental Immunology 2013, 2(3):195-207.
108. Temburni M.K., Jacob M.H. New Functions for Glia in the Brain. Proceedings of the National Academy of Sciences 2001, 98(7):3631-3632.
109. Theberge F.R., Li X., Kambhampati S., Pickens C.L., Laurent R.S., Bossert J.M. Effect of chronic delivery of the toll-like receptor 4 antagonist ()-Naltrexone on incubation of Heroin craving. Biological Psychiatry 2013, 73(8):729-737.
110. Tsigos C., Chrousos G.P. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. Journal of Psychosomatic Research 2002, 53(4):865-871.
111. Wang X., Loram L.C., Ramos K., de Jesus A.J., Thomas J., Cheng K., et al. Morphine activates neuroinflammation in a manner parallel to endotoxin. Proceedings of the National Academy of Sciences 2012, 109(16):6325-6330.
112. Watkins L.R., Hutchinson M.R., Johnston I.N., Maier S.F. Glia: Novel counter-regulators of opioid analgesia. Trends in Neurosciences 2005, 28(12):661-669.
113. Watkins L.R., Hutchinson M.R., Rice K.C., Maier S.F. The 'Toll' of opioid-induced glial activation: Improving the clinical efficacy of opioids by targeting glia. Trends in Pharmacological Sciences 2009, 30(11):581-591.
114. Weber M.D., Frank M.G., Sobesky J.L., Watkins L.R., Maier S.F. Blocking toll-like receptor 2 and 4 signaling during a stressor prevents stress-induced priming of neuroinflammatory responses to a subsequent immune challenge. Brain, Behavior, and Immunity 2013, 32(C):112-121.
115. Williams J.T., Ingram S.L., Henderson G., Chavkin C., von, M Zastrow, Schulz S., et al. Regulation of -opioid receptors: Desensitization, phosphorylation, internalization, and tolerance. Pharmacological Reviews 2012, 65(1):223-254.
116. World Health Organization The ICD-10 classification of mental and behavioural disorders: Diagnostic criteria for research 1993, World Health Organization, Geneva, Switzerland.
117. Wrona D. Neural-immune interactions: An integrative view of the bidirectional relationship between the brain and immune systems. Journal of Neuroimmunology 2006, 172(1-2):38-58.
118. Yang J., Yu J., Jia X., Zhu W., Zhao L., Li S., et al. Inhibition of nuclear factor-kB impairs reconsolidation of morphine reward memory in rats. Behavioural Brain Research 2011, 216(2):592-596.
119. Yirmiya R., Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain, Behavior, and Immunity 2011, 25(2):181-213.
120. Yoon S.Y., Patel D., Dougherty P.M. Minocycline blocks lipopolysaccharide induced hyperalgesia by suppression of microglia but not astrocytes. Neuroscience 2012, 221(C):214-224.
121. Zhang X.-Q., Cui Y., Cui Y., Chen Y., Na X.-D., Chen F.-Y., et al. Activation of P38 signaling in the microglia in the nucleus accumbens contributes to the acquisition and maintenance of morphine-induced conditioned place preference. Brain, Behavior, and Immunity 2012, 26(2):318-325.